PT983381E - Previsão de doença de artéria coronária - Google Patents
Previsão de doença de artéria coronária Download PDFInfo
- Publication number
- PT983381E PT983381E PT98910298T PT98910298T PT983381E PT 983381 E PT983381 E PT 983381E PT 98910298 T PT98910298 T PT 98910298T PT 98910298 T PT98910298 T PT 98910298T PT 983381 E PT983381 E PT 983381E
- Authority
- PT
- Portugal
- Prior art keywords
- coronary artery
- allele
- disease
- artery disease
- marker
- Prior art date
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims description 54
- 108700028369 Alleles Proteins 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 30
- 239000003550 marker Substances 0.000 claims description 26
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 13
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102100039065 Interleukin-1 beta Human genes 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 201000010099 disease Diseases 0.000 description 31
- 108010002352 Interleukin-1 Proteins 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000000589 Interleukin-1 Human genes 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 9
- 210000004351 coronary vessel Anatomy 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 108091008053 gene clusters Proteins 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000028922 artery disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 230000018276 interleukin-1 production Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003234 polygenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- -1 LIFF Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000037340 Rare genetic disease Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 101150076141 rn gene Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/813,456 US6210877B1 (en) | 1997-03-10 | 1997-03-10 | Prediction of coronary artery disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT983381E true PT983381E (pt) | 2007-11-26 |
Family
ID=25212420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98910298T PT983381E (pt) | 1997-03-10 | 1998-03-09 | Previsão de doença de artéria coronária |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6210877B1 (enExample) |
| EP (1) | EP0983381B1 (enExample) |
| JP (2) | JP4250765B2 (enExample) |
| CN (1) | CN100523214C (enExample) |
| AR (1) | AR011943A1 (enExample) |
| AT (1) | ATE370246T1 (enExample) |
| AU (1) | AU738875B2 (enExample) |
| BR (1) | BR9808313A (enExample) |
| CA (1) | CA2282746C (enExample) |
| DE (2) | DE69838250T2 (enExample) |
| DK (1) | DK0983381T3 (enExample) |
| EA (1) | EA199900813A1 (enExample) |
| ES (1) | ES2156843T3 (enExample) |
| GR (1) | GR20010300016T1 (enExample) |
| IL (1) | IL131745A0 (enExample) |
| MX (1) | MXPA99008223A (enExample) |
| NO (1) | NO994365L (enExample) |
| NZ (1) | NZ337642A (enExample) |
| PL (1) | PL335603A1 (enExample) |
| PT (1) | PT983381E (enExample) |
| WO (1) | WO1998040517A1 (enExample) |
| ZA (1) | ZA981937B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
| US6524795B1 (en) | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
| US6720141B1 (en) | 1999-11-01 | 2004-04-13 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for restenosis |
| US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
| US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| US6437216B1 (en) | 1997-11-13 | 2002-08-20 | Interleukin Genetics Inc. | Transgenic models of inflammatory disease |
| GB9723835D0 (en) * | 1997-11-13 | 1998-01-07 | Nicklin Martin | Interleukin knockout |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US20050032077A1 (en) * | 1998-03-10 | 2005-02-10 | Duff Gordon W. | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| US6733967B1 (en) | 1998-04-21 | 2004-05-11 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| WO1999054707A2 (en) * | 1998-04-21 | 1999-10-28 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| US6251598B1 (en) | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| JP2003500005A (ja) * | 1999-02-10 | 2003-01-07 | インターリューキン ジェネティックス インコーポレイテッド | ＩＬ−１β遺伝子の突然変異に基づく治療および診断 |
| JP2003500069A (ja) * | 1999-05-24 | 2003-01-07 | インタールーキン ジェネティックス インク | 再狭窄の診断及び治療薬 |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| US20030152947A1 (en) * | 2001-06-15 | 2003-08-14 | Crossman David C. | Methods for detecting and treating the early onset of aging-related conditions |
| EP1463745A4 (en) * | 2001-11-19 | 2007-11-07 | Interleukin Genetics Inc | FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES |
| US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| EP1327639A1 (en) * | 2002-01-15 | 2003-07-16 | Bayer Ag | Prediction of cardiovascular disease by genetic polymorphisms in cardiovascular associated genes |
| WO2003064600A2 (en) * | 2002-01-25 | 2003-08-07 | Interleukin Genetics, Inc. | The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| BR0314552A (pt) * | 2002-09-30 | 2005-08-09 | Novartis Ag | Métodos para prognosticar elevações de colesterol durante terapia imunossupressora |
| US20050053956A1 (en) * | 2002-11-13 | 2005-03-10 | Dietz Harry C. | Detection of a predisposition for the development of coronary artery disease |
| US20060204962A1 (en) * | 2003-02-03 | 2006-09-14 | Udo Stropp | Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy |
| WO2004081186A2 (en) * | 2003-03-10 | 2004-09-23 | Applera Corporation | Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof |
| CA2566257A1 (en) * | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| US8105775B2 (en) * | 2005-10-25 | 2012-01-31 | Interleukin Genetics, Inc. | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| RU2310862C1 (ru) * | 2006-05-02 | 2007-11-20 | Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ выявления риска развития ишемической болезни сердца |
| US7935498B2 (en) * | 2006-07-07 | 2011-05-03 | Siemens Healthcare Diagnostics Inc. | Methods for identifying patients with increased risk of an adverse cardiovascular event |
| WO2008060627A2 (en) * | 2006-11-15 | 2008-05-22 | Interleukin Genetics, Inc. | The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
| US20090170105A1 (en) * | 2007-11-08 | 2009-07-02 | Interleukin Genetics, Inc. | Diagnostics for Aging-Related Dermatologic Disorders |
| US20100112570A1 (en) * | 2008-10-22 | 2010-05-06 | Interleukin Genetics, Inc. | Genetic Markers for Weight Management and Methods of Use Thereof |
| CN102747075B (zh) * | 2012-06-07 | 2014-07-23 | 中国医学科学院阜外心血管病医院 | 与冠心病相关的6号染色体易感区域标签单核苷酸多态性位点及其组成的单体型与应用 |
| CA3011363A1 (en) | 2016-01-12 | 2017-07-20 | Interleukin Genetics, Inc. | Methods for predicting response to treatment |
| CN106202936A (zh) * | 2016-07-13 | 2016-12-07 | 为朔医学数据科技（北京）有限公司 | 一种疾病风险预测方法及系统 |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| CN110277137B (zh) * | 2019-06-13 | 2022-03-18 | 南方医科大学顺德医院(佛山市顺德区第一人民医院) | 一种用于检测冠心病的基因芯片信息处理系统及方法 |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110920A (en) | 1982-01-22 | 1992-05-05 | Cetus Corporation | HLA typing method and DNA probes used therein |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4623619A (en) | 1982-03-03 | 1986-11-18 | Nordisk Insulinlaboratorium | Method for the determination of liability in human individuals to develop atherosclerosis |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5268267A (en) | 1987-08-21 | 1993-12-07 | The General Hospital Corporation | Method for diagnosing small cell carcinoma |
| GB9301453D0 (en) * | 1993-01-26 | 1993-03-17 | Clonit Spa | Nucleotide proves |
| US5658729A (en) | 1994-10-11 | 1997-08-19 | The University Of British Columbia | Method, reagent and kit for evaluating susceptibility to premature atherosclerosis |
| US5686246A (en) | 1995-08-03 | 1997-11-11 | Kornman; Kenneth S. | Detecting genetic predisposition to periodontal disease |
| US5698399A (en) | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
| US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
-
1997
- 1997-03-10 US US08/813,456 patent/US6210877B1/en not_active Expired - Fee Related
-
1998
- 1998-03-06 ZA ZA9801937A patent/ZA981937B/xx unknown
- 1998-03-09 NZ NZ337642A patent/NZ337642A/en unknown
- 1998-03-09 CA CA002282746A patent/CA2282746C/en not_active Expired - Fee Related
- 1998-03-09 ES ES98910298T patent/ES2156843T3/es not_active Expired - Lifetime
- 1998-03-09 MX MXPA99008223A patent/MXPA99008223A/es unknown
- 1998-03-09 AT AT98910298T patent/ATE370246T1/de not_active IP Right Cessation
- 1998-03-09 WO PCT/US1998/004725 patent/WO1998040517A1/en not_active Ceased
- 1998-03-09 CN CNB988049155A patent/CN100523214C/zh not_active Expired - Fee Related
- 1998-03-09 DK DK98910298T patent/DK0983381T3/da active
- 1998-03-09 DE DE69838250T patent/DE69838250T2/de not_active Expired - Lifetime
- 1998-03-09 AU AU64574/98A patent/AU738875B2/en not_active Ceased
- 1998-03-09 EA EA199900813A patent/EA199900813A1/ru unknown
- 1998-03-09 BR BR9808313-9A patent/BR9808313A/pt not_active Application Discontinuation
- 1998-03-09 PT PT98910298T patent/PT983381E/pt unknown
- 1998-03-09 AR ARP980101032A patent/AR011943A1/es unknown
- 1998-03-09 DE DE0983381T patent/DE983381T1/de active Pending
- 1998-03-09 PL PL98335603A patent/PL335603A1/xx unknown
- 1998-03-09 IL IL13174598A patent/IL131745A0/xx unknown
- 1998-03-09 JP JP53974098A patent/JP4250765B2/ja not_active Expired - Fee Related
- 1998-03-09 EP EP98910298A patent/EP0983381B1/en not_active Expired - Lifetime
-
1999
- 1999-09-09 NO NO994365A patent/NO994365L/no unknown
-
2001
- 2001-04-30 GR GR20010300016T patent/GR20010300016T1/el unknown
-
2008
- 2008-10-29 JP JP2008277752A patent/JP2009077727A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009077727A (ja) | 2009-04-16 |
| EP0983381A1 (en) | 2000-03-08 |
| ES2156843T1 (es) | 2001-08-01 |
| EP0983381B1 (en) | 2007-08-15 |
| CN100523214C (zh) | 2009-08-05 |
| DE69838250T2 (de) | 2008-05-08 |
| EA199900813A1 (ru) | 2000-06-26 |
| PL335603A1 (en) | 2000-05-08 |
| CA2282746A1 (en) | 1998-09-17 |
| ES2156843T3 (es) | 2008-04-16 |
| ATE370246T1 (de) | 2007-09-15 |
| US6210877B1 (en) | 2001-04-03 |
| JP2001514522A (ja) | 2001-09-11 |
| CN1255948A (zh) | 2000-06-07 |
| WO1998040517A1 (en) | 1998-09-17 |
| EP0983381A4 (en) | 2004-05-12 |
| AU6457498A (en) | 1998-09-29 |
| NO994365D0 (no) | 1999-09-09 |
| DK0983381T3 (da) | 2007-12-17 |
| NO994365L (no) | 1999-11-09 |
| NZ337642A (en) | 2001-02-23 |
| DE69838250D1 (de) | 2007-09-27 |
| CA2282746C (en) | 2009-02-24 |
| MXPA99008223A (es) | 2003-07-21 |
| JP4250765B2 (ja) | 2009-04-08 |
| AU738875B2 (en) | 2001-09-27 |
| IL131745A0 (en) | 2001-03-19 |
| DE983381T1 (de) | 2000-11-09 |
| ZA981937B (en) | 1999-09-06 |
| BR9808313A (pt) | 2000-05-16 |
| AR011943A1 (es) | 2000-09-13 |
| GR20010300016T1 (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT983381E (pt) | Previsão de doença de artéria coronária | |
| Humphries et al. | The interleukin-6− 174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men | |
| Austin | Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype | |
| Lehtimäki et al. | Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease | |
| Bekris et al. | Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels | |
| US5571671A (en) | Method for detecting alzheimer's disease | |
| Schena et al. | ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis | |
| Powell et al. | Evidence against a role for polymorphisms at tumor necrosis factor, interleukin-1 and interleukin—1 receptor antagonist gene loci in the regulation of disease severity in acute pancreatitis | |
| Myant et al. | Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. | |
| JPH10500288A (ja) | アポリポ蛋白質ｅの多形性およびアルツハイマー病の治療 | |
| US7939287B2 (en) | Methods of identifying a subject having or at risk of having or developing coronary artery disease | |
| CN101356286A (zh) | 心血管病症的诊断和疗法 | |
| US6555320B1 (en) | Methods and materials for evaluating rheumatoid arthritis | |
| Barst et al. | Genetics and immunogenetic aspects of primary pulmonary hypertension | |
| Bruikman et al. | Genetic variants in SUSD2 are associated with the risk of ischemic heart disease | |
| Granel et al. | Genetic susceptibility to systemic sclerosis: From clinical aspect to genetic factor analyses | |
| US20080268478A1 (en) | Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation | |
| Nakamura | Amyloid A amyloidosis secondary to rheumatoid arthritis: an uncommon yet important complication | |
| PT1471143E (pt) | Método de avaliação para avaliar o aparecimento ou a possibilidade do aparecimento de artrite reumatóide | |
| US20050048492A1 (en) | Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining cyp46 genotype | |
| EP1578252A2 (en) | Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases | |
| CZ9903182A3 (cs) | Předpověď onemocnění věnčitých tepen | |
| US20030044810A1 (en) | Methods, compositions, and kits relating to cardiovascular disease | |
| Colonna | Identification of High Risk Coronary Artery Disease patient by Molecular Techiniques: the MEF-2A paradigm | |
| LeMaire et al. | Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease... |